Eledon Cost Of Revenue from 2010 to 2024
| ELDN Stock | USD 4.50 0.03 0.67% |
Cost Of Revenue | First Reported 2010-12-31 | Previous Quarter 374 K | Current Value 392.7 K | Quarterly Volatility 150.4 K |
Check Eledon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eledon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 494.4 K, Interest Expense of 1 M or Selling General Administrative of 10.4 M, as well as many indicators such as Price To Sales Ratio of 149, Dividend Yield of 9.0E-4 or PTB Ratio of 6.5 K. Eledon financial statements analysis is a perfect complement when working with Eledon Pharmaceuticals Valuation or Volatility modules.
Eledon | Cost Of Revenue |
Latest Eledon Pharmaceuticals' Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of Eledon Pharmaceuticals over the last few years. Cost of Revenue is found on Eledon Pharmaceuticals income statement and represents the costs associated with goods and services Eledon Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Eledon Pharmaceuticals' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eledon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
Eledon Cost Of Revenue Regression Statistics
| Arithmetic Mean | 125,133 | |
| Geometric Mean | 9,028 | |
| Coefficient Of Variation | 120.19 | |
| Mean Deviation | 126,521 | |
| Median | 35,000 | |
| Standard Deviation | 150,403 | |
| Sample Variance | 22.6B | |
| Range | 392.6K | |
| R-Value | 0.88 | |
| Mean Square Error | 5.4B | |
| R-Squared | 0.78 | |
| Significance | 0.000014 | |
| Slope | 29,669 | |
| Total Sum of Squares | 316.7B |
Eledon Cost Of Revenue History
About Eledon Pharmaceuticals Financial Statements
Eledon Pharmaceuticals investors utilize fundamental indicators, such as Cost Of Revenue, to predict how Eledon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 374 K | 392.7 K |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eledon Stock
| 0.67 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
Moving against Eledon Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.78 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.76 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.65 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eledon Pharmaceuticals Correlation against competitors. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.